OrbiMed’s Whitehawk Therapeutics WHWK Stock Holding History

OrbiMed’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.4M	Hold	4,166,000	–	–	0.28%	67
2025 Q4	$10.1M	Hold	4,166,000	–	–	0.21%	81
2025 Q3	$7.92M	Hold	4,166,000	–	–	0.19%	77
2025 Q2	$7.79M	Hold	4,166,000	–	–	0.19%	67
2025 Q1	$7.42M	Buy	+4,166,000	New	+$10.9M	0.18%	71
2022 Q1	–	Sell	-127,600	Closed	-$3.08M	–	164
2021 Q4	$3.08M	Sell	127,600 -218,662	-63%	-$5.49M	0.04%	145
2021 Q3	$10.2M	Sell	346,262 -1	-0%	-$30	0.11%	126
2021 Q2	$8.78M	Hold	346,263	–	–	0.09%	132
2021 Q1	$6.7M	Hold	346,263	–	–	0.06%	133
2020 Q4	$5.09M	Hold	346,263	–	–	0.04%	140
2020 Q3	$7.79M	Hold	346,263	–	–	0.1%	114
2020 Q2	$6.49M	Hold	346,263	–	–	0.09%	112
2020 Q1	$2.86M	Hold	346,263	–	–	0.05%	119
2019 Q4	$3.24M	Hold	346,263	–	–	0.05%	112
2019 Q3	$3.53M	Hold	346,263	–	–	0.07%	100
2019 Q2	$4.73M	Hold	346,263	–	–	0.07%	113
2019 Q1	$4.68M	Hold	346,263	–	–	0.07%	110
2018 Q4	$8.83M	Hold	346,263	–	–	0.16%	91
2018 Q3	$16M	Hold	346,263	–	–	0.19%	96
2018 Q2	$21.6M	Buy	+346,263	New	+$20.9M	0.26%	87

Other funds holding WHWK

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

KCA

KVP Capital Advisors San Francisco, California $134M AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Yu Fan $97M AUM 57.2% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

OrbiMed's WHWK Position: Q1 2026 in Review

OrbiMed held its Whitehawk Therapeutics (WHWK) position steady in Q1 2026 at 4,166,000 shares worth $14.4M. The position accounts for 0.28% of the portfolio, ranked #67.

OrbiMed first reported a position in WHWK in Q2 2018 and has held it in 20 quarters since. The position peaked at $21.6M in Q2 2018. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

OrbiMed held 4,166,000 shares of Whitehawk Therapeutics worth $14.4M as of Q1 2026.
OrbiMed left its Whitehawk Therapeutics share count unchanged in Q1 2026.
Whitehawk Therapeutics made up 0.28% of OrbiMed's portfolio in Q1 2026, its #67 holding.
OrbiMed first reported a position in Whitehawk Therapeutics in Q2 2018 and has held it in 20 quarters since.
OrbiMed's Whitehawk Therapeutics position peaked at $21.6M in Q2 2018.
62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.